Lexel – Nestor Rava, CEO – Argentina
The CEO and one of the founders of Lexel explains how the company adapts its medical devices to the specifications required by their international customers. Why did Lexel enter…
The National Administration of Drugs, Foods and Medical Devices (ANMAT) is an agency decentralized from the National Public Administration that was created by decree 1490/92.It cooperates in the protection of human health by assuring the quality of the products it regulates: drugs, foodstuff, medicinal products, diagnosis reagents, cosmetic products, dietary supplements and household cleaning products.Having a nationwide jurisdiction, it was created in August 1992 and ever since its group of professionals and technicians have worked with modern technology in order to efficiently fulfill the process of authorization, registration, standardization, vigilance and monitoring of the products used in the human medicine, food and cosmetic fields.Granted with an economic and financial autarky, in the technical and scientific field it is under the authority of the Ministry of Health Secretariat of Policies, Regulation and Institutes standards and guidelines. In this framework, ANMAT main objective is to guarantee that drugs, foodstuff, medical devices at the reach of the public be compliant in terms of efficacy (fulfillment of the therapeutic, nutritional or diagnostic objective), safety (high benefit/risk ratio) and quality (by meeting the citizens´ needs and expectations).
CONTACT DETAILS
Av. De Mayo 869, C1084AAD – CABA
Tel: +54 (11) 4340-0800
The CEO and one of the founders of Lexel explains how the company adapts its medical devices to the specifications required by their international customers. Why did Lexel enter…
Carlos Chiale, National Administrator of ANMAT, discusses the agency’s latest strategy implementation and its pioneering work in the area of fighting drug falsification. Could you provide a historical overview…
The general manager of Sandoz South Latam weighs up the factors that have allowed his company to be the leader in biosimilars and differentiated generics. Could you please…
The vice president of Laboratorios Beta discusses the factors of why his organization is on the way to consolidating its different business lines and becoming a pure pharmaceutical company. …
The general director of pharma in Argentina for the Bagó group explains why his group has planned that 75 percent of turnover will come from international markets in the coming years. 2014 marks…
The executive coordinator of GACTEC maps the current level of science and technology in Argentina and outlines the country’s ambitions in this area, which is to have an impact on innovation at…
The President of Argenomics highlights the position of his company as the bridge between science and business in Argentina. Could you please provide an historical overview of Argenomics? Several…
The general manager of Ferring Argentina believes that the country has one of the strongest social security systems in Latin America, with high reimbursement levels and coverage for most chronic…
The general manager of Roche Argentina weighs up the factors that have allowed the country to be included among the top three performing markets in the region for Roche, and…
The general manager of Gennoma Laboratorios Argentina weighs up the factors of why raising brand awareness using public television is the key success to his company communication strategy. When…
“In the last decade, as a result of high and sustained growth, the Argentine pharmaceutical industry increased production by more than 240 percent, which speaks volumes about the capacity of…
The country president of AstraZeneca Argentina discusses the country’s patent laws, the work being done to bring innovation back to Argentina, and the challenge of a strong branded generics market…
See our Cookie Privacy Policy Here
